336 related articles for article (PubMed ID: 28335642)
1. Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.
Marks DI; Liu Q; Slavin M
Expert Rev Anti Infect Ther; 2017 May; 15(5):493-502. PubMed ID: 28335642
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
3. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
4. Secondary antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients with invasive fungal infection.
Pepeler MS; Yildiz Ş; Yegin ZA; Özkurt ZN; Tunçcan ÖG; Erbaş G; Köktürk N; Kalkanci A; Yildirim Z
J Infect Dev Ctries; 2018 Sep; 12(9):799-805. PubMed ID: 31999640
[TBL] [Abstract][Full Text] [Related]
5. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
Mauskopf J; Chirila C; Graham J; Gersten ID; Leather H; Maziarz RT; Baden LR; Bolaños-Meade J; Brown JM; Walsh TJ; Horowitz MH; Kurtzberg J; Marr KA; Wingard JR
Am J Health Syst Pharm; 2013 Sep; 70(17):1518-27. PubMed ID: 23943184
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic stem cell transplant.
Walker BS; Schmidt RL; Tantravahi S; Kim K; Hanson KE
Transpl Infect Dis; 2019 Oct; 21(5):e13148. PubMed ID: 31325373
[TBL] [Abstract][Full Text] [Related]
7. Antifungal prophylaxis in haematology patients: the role of voriconazole.
Hicheri Y; Cook G; Cordonnier C
Clin Microbiol Infect; 2012 Apr; 18 Suppl 2():1-15. PubMed ID: 22409648
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of voriconazole, fluconazole, and amphotericin B for invasive fungal infections following allogeneic hematopoietic stem cell transplantation in Mexico.
Morfín-Otero R; Alvarado-Ibarra M; Rodriguez-Noriega E; Resendiz-Sanchez J; Patel DA; Stephens JM; Di Fusco M; Mendoza CF; Charbonneau C
Clinicoecon Outcomes Res; 2018; 10():511-520. PubMed ID: 30233223
[TBL] [Abstract][Full Text] [Related]
9. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.
Zhao YJ; Khoo AL; Tan G; Teng M; Tee C; Tan BH; Ong B; Lim BP; Chai LY
Antimicrob Agents Chemother; 2016 Jan; 60(1):376-86. PubMed ID: 26525782
[TBL] [Abstract][Full Text] [Related]
10. Sequential systematic anti-mold prophylaxis with micafungin and voriconazole results in very low incidence of invasive mold infections in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rosillo C; Avila AM; Huang YT; Devlin S; Cho C; Montoro J; Maloy MA; Papanicolaou GA; Barba P; Perales MA
Transpl Infect Dis; 2018 Aug; 20(4):e12897. PubMed ID: 29668073
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
12. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
13. [Prophylactic strategies for invasive fungal infections after allogeneic hematopoietic stem cell transplantation].
Asano-Mori Y
Rinsho Ketsueki; 2016; 57(10):2208-2217. PubMed ID: 27795532
[TBL] [Abstract][Full Text] [Related]
14. An open-label trial of the prophylactic administration of voriconazole in patients who undergo allogeneic hematopoietic stem cell transplantation: study protocol.
Kunitomi A; Hasegawa Y; Hashimoto H; Saito AM; Iida H
Nagoya J Med Sci; 2018 Nov; 80(4):591-595. PubMed ID: 30587873
[TBL] [Abstract][Full Text] [Related]
15. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents.
Strasfeld L; Weinstock DM
Expert Rev Anti Infect Ther; 2006 Jun; 4(3):457-68. PubMed ID: 16771622
[TBL] [Abstract][Full Text] [Related]
16. Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts.
McCoy D; Depestel DD; Carver PL
Pharmacotherapy; 2009 Nov; 29(11):1306-25. PubMed ID: 19857148
[TBL] [Abstract][Full Text] [Related]
17. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis.
Ziakas PD; Kourbeti IS; Mylonakis E
Clin Ther; 2014 Feb; 36(2):292-306.e1. PubMed ID: 24439393
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.
Sánchez-Ortega I; Patiño B; Muñoz C; Arnan M; Peralta T; Clopés A; de Sevilla AF; Duarte RF
J Med Econ; 2013; 16(6):736-43. PubMed ID: 23541251
[TBL] [Abstract][Full Text] [Related]
19. Antifungal prophylaxis in adult hematopoietic stem cell transplant recipients.
Tamura K; Drew R
Drugs Today (Barc); 2008 Jul; 44(7):515-30. PubMed ID: 18806902
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden.
Floros L; Kuessner D; Posthumus J; Bagshaw E; Sjölin J
BMC Infect Dis; 2019 Feb; 19(1):134. PubMed ID: 30744563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
